OKYO Pharma Announces Distinguished Ophthalmologists with Expertise in the Medical and Surgical Treatment of Ocular Surface Diseases Join its Scientific Advisory Board - Seite 2
"Following our positive safety and efficacy results in our Phase 2 trial in DED, we are pleased to add eminent physicians with a deep understanding of ocular surface diseases and neuropathic corneal pain to OKYO’s Scientific Advisory Board," said Gary S. Jacob PhD, CEO of OKYO Pharma. "As we continue to focus our efforts on the advancement of OK-101 for the millions of patients who suffer from DED and NCP, Drs. Perez, Galor, Milner, and our existing Scientific Advisory Board Members Drs. Pedram Hamrah and Jay Pepose, can offer unmatched insight into their respective clinical development programs. OKYO's Scientific Advisory Board now has an ideal blend of clinical expertise, including ocular surface disease and neuropathic corneal pain, from the leading experts in those fields."
On January 8, 2024, OKYO announced positive safety and efficacy results in its Phase 2, randomized, double-masked, placebo-controlled trial evaluating the safety and efficacy of OK-101 ophthalmic solution in subjects with DED. This first-in-human trial of OK-101 established a clear and informed path for further development of OK-101 in Phase 3 registration trials.
OKYO management plans to host a conference call to provide further data on the trial results once the Company has finished a more comprehensive analysis of the data from the trial. The conference call is planned for Q1, 2024.
About Dry Eye Disease
Dry eye disease is a common condition that occurs when an individual’s tears are unable to adequately lubricate the eyes. This condition affects approximately 49 million people in the U.S. alone
and has been a difficult one to positively diagnose and to treat due to the multifactorial nature of the condition. Several contributing factors can lead to this condition, including age, sex,
certain medical conditions, reduced tear production and tear film dysfunction. Tear film instability typically leads to inflammation and damage to the ocular surface.
Lesen Sie auch
About NCP
Neuropathic corneal pain (NCP) is a condition that causes the eyes, face, or head to be painful and overly sensitive. The exact cause of NCP is unknown but thought to
result from nerve damage to the cornea combined
with inflammation. NCP, which can exhibit as a severe, chronic, or debilitating condition in patients suffering from a host of ophthalmic conditions, is
presently treated by various topical and systemic treatments in an off-label fashion. There are no approved commercial treatments currently available for this condition.